Effect of fragmentation of intravitreal dexamethasone implant in patients with macular edema due to branch retinal vein occlusion

Poster Details

First Author: J.Im SOUTH KOREA

Co Author(s):    J. Kim   D. Park                          

Abstract Details


To evaluate the effect of fragmentation of intravitreal dexamethasone implant in eyes with macular edema (ME) secondary to branch retinal vein occlusion (BRVO).


Prospective non-randomized cohort study. The study group consisted of all consecutive patients who underwent intravitreal dexamethasone implant for ME due to BRVO between October 2013 and December 2014.


Enrolled patients were divided into the single-piece group and multi-piece group by the fragmentation of the dexamethasone implant at postoperative day 1. Slit-lamp biomicroscopy, measurement of best-corrected visual acuity (BCVA), measurement of intraocular pressure (IOP) by applanation tonometry, and central subfield thickness (CST) with spectral-domain optical coherence tomography were performed at baseline and monthly follow-up visit until 6 months.


Among 68 eyes (68 patients) with dexamethasone implant, 62 eyes (91.2%) showed a single-piece and six eyes (8.8%) showed a multi-piece implant. The number of dexamethasone implant fragments were significantly different between two groups at each follow-up visit (P < 0.001, respectively). Clinical outcomes including BCVA and CST had no significant difference between two groups at each follow-up visit (P > 0.05, respectively). Recurrence of ME occurred in 35 eyes (56.5%) of single-piece group and three eyes (50.0%) of multi-piece group during 6 months, which was not statistically different (P = 0.684). Number of patients with the IOP elevation and cataract progression were not different between two groups (P > 0.05, respectively).


These results suggest that after intravitreal dexamethasone implant, the single-piece and multi-piece groups did not differ in clinical outcomes during 6 months. In addition, both groups did not differ in the frequency of adverse events significantly.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy